Medicenna Therapeutics Insider Trading
TSX MDNA
5
All Trades
2
Significant
3
Notable
2
Clusters
0
Repeat
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Medicenna Therapeutics | ββββββ | ββββββββ | ββ-βββ-26 | βββ,βββ | $β.ββ | $βββ,βββ | βββ,βββ | ββ% | ββββββββ |
| Medicenna Therapeutics | ββββββ | ββββββββ | ββ-βββ-26 | βββ,βββ | $β.ββ | $βββ,βββ | βββ,βββ | ββ% | ββββββββ |
| Medicenna Therapeutics | ββββββ | ββββββββ | ββ-βββ-26 | βββ,βββ | $β.ββ | $βββ,βββ | βββ,βββ | ββ% | ββββββββ |
| Medicenna Therapeutics | ββββββ | ββββββββ | ββ-βββ-26 | βββ,βββ | $β.ββ | $βββ,βββ | βββ,βββ | ββ% | ββββββββ |
| Medicenna Therapeutics | ββββββ | ββββββββ | ββ-βββ-26 | βββ,βββ | $β.ββ | $βββ,βββ | βββ,βββ | ββ% | ββββββββ |
| Company | Insider | Title | Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|
| Medicenna Therapeutics | Beraldo, Albert | Director | 15-Dec-25 | 85,000 | $1.12 | $94,818 | 477,113 | 22% | Significant Cluster |
| Medicenna Therapeutics | Merchant, Fahar | CEO | 15-Dec-25 | 32,000 | $1.11 | $35,520 | 78,000 | 70% | Notable Cluster |
| Medicenna Therapeutics | Merchant, Fahar | CEO | 06-Mar-25 | 31,000 | $1.00 | $31,000 | 31,000 | New | Notable |
| Medicenna Therapeutics | Beraldo, Albert | Director | 13-Feb-25 | 48,800 | $1.26 | $61,377 | 392,113 | 14% | Significant |
| Medicenna Therapeutics | Hyman, David | CFO | 09-Jan-25 | 20,000 | $1.45 | $29,000 | 40,000 | 100% | Notable |
Stock Chart
Related Companies to Explore
Company Info
Medicenna Therapeutics Corp., established in 2013, is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative, highly selective cytokine-based therapies to treat cancer and other diseases. The company’s proprietary technology platforms include Superkines and Empowered Cytokines, designed to enhance therapeutic efficacy while minimizing side effects. Medicennaβs work is rooted in developing advanced immunotherapies that aim to harness the bodyβs natural immune response to combat complex conditions. Headquartered in Toronto, Canada, Medicenna operates at the intersection of cutting-edge research and clinical application. The company is publicly traded on both the Toronto Stock Exchange (TSX) and the NASDAQ under the ticker symbol MDNA. With a commitment to improving patient outcomes through precision medicine, Medicenna continues to advance its portfolio of targeted therapies in alignment with its mission to transform the treatment landscape.